Committed to the Development of Kinase Inhibitor Therapeutics

Inhibikase Therapeutics is a company focused on developing and commercializing small-molecule kinase inhibitor therapeutics for the safe and effective treatment of neurological diseases inside and outside of the brain, on developing technologies to improve the efficiency of drug delivery and drug penetration of kinase inhibitor therapies inside and outside of the brain and focused on developing novel strategies for the treatment of neurological infections.

Our RAMP™ Drug Innovation Engine

Our proprietary Re-engineering Approach with Metabolism Preserved (RAMP™) drug innovation engine enables us to design and develop novel small-molecule product candidates that leverage the clinical experience gained from currently marketed kinase inhibitor drugs and imprints the properties we wish to preserve onto new molecular entities. Using this established knowledge as a starting point, we pursue the clinically validated kinase inhibitors as targets for the creation of novel drugs with enhanced efficacy and improved safety that may be administered chronically and systemically to treat kinase inhibitor-sensitive neurological and non-neurological diseases. 

Our Prodrug Technology

Our Prodrug technology is a technology platform that enables greater control over non-hematological side effects common to kinase inhibitor therapies, such as nausea or diarrhea, and may improve drug delivery into the target tissue.  Using a proprietary set of linkers and attachment points, our oral prodrugs are absorbed intact and then fall apart into the active ingredient and the linker.  We are applying this approach to potentially improve safety and tolerability of kinase inhibitors for a variety of indications. 

Three Novel Small-molecule Candidates

Our initial focus is on the development of product candidates we have generated using RAMP that use the same targeting strategy—blocking the activation of Abelson tyrosine kinases (Abl kinases)—to address two distinct unmet needs for life-threatening infections and neurodegenerative CNS diseases. Our product candidates include:

  • A disease-modifying therapy that we believe halts the progression and reverses functional loss arising from Parkinson’s disease in the brain and gastrointestinal (GI) tract while simultaneously nearly clearing the toxic form of alpha-synuclein believed to be the cause of the disease.
  • A treatment for stable-phase Chronic Myelogenous Leukemia (CML) with a prodrug of the anticancer agent imatinib, that we believe will:
    • have a superior safety profile;
    • improve drug absorption;
    • lower the dose required for efficacy; and
    • suppress gastrointestinal adverse events  associated with imatinib therapy.
  • A companion therapeutic that we believe may remove the risk of Progressive Multifocal Leukoencephalopathy (PML), a rare but rapidly fatal brain infection, by blocking the production of John Cunningham virus (JCV), the cause of PML. Onset of JCV has been linked to treatment with more than 15 medications that are used to treat cancer and autoimmune diseases, such as multiple sclerosis.   

IkT-148009 for Parkinson’s Disease

Our lead small-molecule product candidate, IkT-148009, is an Abelson tyrosine kinase inhibitor (a c-Abl inhibitor) that targets underlying disease mechanisms to halt the progression and reverse functional loss of Parkinson’s disease in the brain and the GI complications of Parkinson’s disease. We believe that IkT-148009 is the only disease-modifying drug in development for Parkinson’s disease that is focused on a clinically validated target and that IkT-148009 has the potential to be the first disease-modifying therapy for Parkinson’s disease that blocks a checkpoint on the pathway that drives Parkinson’s disease progression.

About IkT-148009

IkT-001Pro Chronic Myeloid Leukemia

Our second small-molecule product candidate, IkT-001Pro, is a prodrug of the anticancer agent imatinib (marketed as Gleevec®). IkT-001Pro alters the way imatinib is absorbed in the GI tract, which we believe suppresses GI distress experienced by up to one-half of Gleevec® patients daily. IkT-001Pro also delivers more imatinib into the tissues due to its altered absorption characteristics, thereby potentially reducing the dose required to achieve efficacy for imatinib-sensitive cancers. By lowering the dose, we believe IkT-001Pro may have an improved safety profile, which may reduce the daily burden of therapy for Gleevec® patients.

About IkT-001Pro

IkT-01427 for Progressive Multifocal Leukoencephalopathy

Our third small-molecule product candidate, IkT-01427, is an Abelson tyrosine kinase inhibitor (a c-Abl inhibitor) that we believe suppresses the reproduction of John Cunningham (JC) virus in the body, thereby removing the sole risk factor for the cause of Progressive Multifocal Leukoencephalopathy (PML). PML is a rare disease that causes a rapidly fatal brain infection. IkT-01427 is positioned as a first-in-class companion therapeutic for any drug that carries a PML black box warning, including drugs for multiple sclerosis, Crohn’s disease, ulcerative colitis, hematological cancers, and organ transplantation.

About IkT-01427

Critical Roles Protein Kinases Play

The development of new therapies for neurodegenerative diseases has lagged behind other drug development areas, despite a growing global need for novel therapeutic approaches. A burgeoning body of research is revealing the critical roles protein kinases play in the molecular mechanisms underlying neurodegenerative diseases—yet the development of kinase-targeted therapies for neurodegenerative diseases remains a challenge due to specific issues associated with developing and commercializing drugs that treat neurodegeneration inside and outside of the brain. 

We are taking a risk-reducing approach to neurodegenerative drug development by leveraging an established understanding of marketed kinase inhibitor drugs to develop a new generation of targeted therapies that may be administered chronically and systemically to patients with infectious or neurodegenerative diseases.

We believe that we are at the forefront of improving treatment outcomes in kinase-sensitive neurodegenerative diseases.